Press release
Chronic Hepatitis B (CHB) market is expected to reach USD 9.8 billion by 2034
Chronic Hepatitis B
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71733
While vaccines prevent new infections, millions remain chronically infected. Current therapies such as nucleos(t)ide analogues (NAs) and interferons suppress viral replication but rarely achieve a cure. With global health agencies, including WHO, aiming to eliminate viral hepatitis as a public health threat by 2030, the CHB market is positioned for growth through innovation, improved access, and wider screening.
Market Overview
• Market Size (2024): USD 5.6 billion
• Forecast (2034): USD 9.8 billion
• CAGR (2025-2034): 5.9%
Market expansion is supported by strong demand for antivirals, pipeline therapies targeting functional cure, and large unmet needs in Asia and Africa.
Key Highlights:
• Current therapies include tenofovir and entecavir (oral NAs) as standard care.
• Novel agents in development aim for functional cure (siRNA, capsid inhibitors, immune modulators).
• Increasing vaccination programs reducing new infections, but chronic cases sustain demand.
• Asia-Pacific accounts for the majority of the global HBV burden.
Segmentation Analysis
By Product Type:
• Antivirals (Nucleos(t)ide Analogues)
o Tenofovir
o Entecavir
o Lamivudine (limited use due to resistance)
• Immunomodulators
o Pegylated Interferon-alpha
• Pipeline Therapies
o siRNA-Based Therapies
o Capsid Assembly Modulators
o Entry Inhibitors
o Therapeutic Vaccines
• Supportive Care
o Antivirals for co-infections (HIV/HBV, HBV/HDV)
o Liver-protective agents
By Platform:
• Small Molecules
• Biologics
• RNA-based Drugs
• Vaccines
By Technology:
• RNA Interference (siRNA, antisense)
• Capsid Assembly Inhibitors
• Immunotherapy Platforms
• Next-Gen Diagnostic Tools
By End Use:
• Hospitals
• Specialty Clinics (Hepatology, Infectious Disease)
• Diagnostic Laboratories
• Research Institutes
By Application:
• HBeAg-Positive CHB
• HBeAg-Negative CHB
• Cirrhosis and Advanced Fibrosis
• Clinical Research
Segmentation Summary:
Antivirals dominate the market today, but the pipeline of siRNA, capsid inhibitors, and immune therapies could redefine the treatment landscape. Hospitals and specialty clinics remain central to care, with diagnostics ensuring early detection and monitoring.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71733/chronic-hepatitis-b-market
Regional Analysis
North America
• ~28% market share in 2024.
• Advanced adoption of antivirals, high healthcare spending, and strong pipeline trials.
• U.S. leading in siRNA and immune therapy clinical research.
Europe
• ~24% share.
• Germany, UK, and France adopting novel diagnostic and therapeutic solutions.
• EMA incentives supporting HBV functional cure research.
Asia-Pacific
• Largest and fastest-growing region (~40% share, CAGR ~7.2%).
• China, India, and Southeast Asia have the highest global burden of CHB.
• Government programs for vaccination, screening, and access to antivirals expanding.
Middle East & Africa
• High prevalence but limited access to advanced drugs.
• Growing international support programs to improve HBV management.
Latin America
• Brazil and Mexico drive regional growth.
• Rising access to antivirals and diagnostic testing.
Regional Summary:
Asia-Pacific dominates due to its massive patient pool, while North America and Europe focus on innovation. Africa represents the most critical need for improved HBV access and funding.
Market Dynamics
Key Growth Drivers:
• High global prevalence of HBV infection.
• Expanding access to antivirals in emerging markets.
• Strong research focus on functional cure beyond viral suppression.
• Government and WHO-driven elimination initiatives.
Key Challenges:
• Current therapies rarely achieve complete cure.
• Rising drug resistance in some regions.
• Limited diagnosis rates - only ~10% of patients are aware of their infection.
• Cost and accessibility barriers in low-income regions.
Latest Trends:
• siRNA and antisense therapies showing promise in clinical trials.
• Capsid assembly modulators emerging as a new drug class.
• Combination regimens (antivirals + immune modulators) being tested for cure.
• AI-driven diagnostics improving early detection and patient monitoring.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71733
Competitor Analysis
Major Players in the Market:
• Gilead Sciences, Inc. (Viread, Vemlidy)
• Bristol Myers Squibb (Baraclude - Entecavir)
• Roche Holding AG
• Novartis AG
• Arrowhead Pharmaceuticals, Inc. (siRNA pipeline)
• Alnylam Pharmaceuticals, Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• GlaxoSmithKline plc
• Assembly Biosciences, Inc. (capsid inhibitors)
• Vir Biotechnology, Inc.
Competitive Summary:
Gilead and BMS lead with established antivirals, while Arrowhead, Alnylam, and Assembly Biosciences drive the next generation of siRNA and capsid modulators. Vir Biotechnology and J&J are advancing immunotherapy candidates. Competition is focused on achieving a functional cure and reducing lifetime therapy dependence.
Conclusion
The Chronic Hepatitis B (CHB) Market, valued at USD 5.6 billion in 2024, is projected to reach USD 9.8 billion by 2034, growing at a CAGR of 5.9%. Rising global prevalence, continued antiviral demand, and strong functional cure pipelines will drive steady market growth.
Key Takeaways:
• Antivirals dominate today, but novel therapies aim for a cure.
• Asia-Pacific holds the largest burden and fastest growth.
• North America and Europe lead in innovation and trials.
• WHO's 2030 elimination goals will accelerate investments and access.
The next decade will reshape CHB management, moving from lifelong suppression to potential cure, powered by siRNA, capsid inhibitors, and immune modulators, creating strong opportunities for pharma innovators and healthcare providers.
This report is also available in the following languages : Japanese (慢性B型肝炎市場), Korean (만성 B형 간염 시장), Chinese (慢性乙型肝炎市场), French (Marché de l'hépatite B chronique), German (Markt für chronische Hepatitis B), and Italian (Mercato dell'epatite B cronica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71733/chronic-hepatitis-b-market#request-a-sample
Our More Reports:
Night Vision Disturbances Market
https://exactitudeconsultancy.com/reports/72294/night-vision-disturbances-market
Uveitis Market
https://exactitudeconsultancy.com/reports/72295/uveitis-market
Dry AMD Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72296/dry-amd-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B (CHB) market is expected to reach USD 9.8 billion by 2034 here
News-ID: 4177407 • Views: …
More Releases from Exactitude Consultancy
Helicobacter pylori (H. pylori) Infections Market is expected to reach $9.1 bill …
Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that colonizes the stomach lining, causing chronic gastritis, peptic ulcers, and significantly increasing the risk of gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. It affects nearly half of the global population, though prevalence varies by geography, socioeconomic conditions, and sanitation levels.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71739
Management of H. pylori infections typically relies on antibiotic-based eradication therapies, combined…
Epidemic Keratoconjunctivitis (EKC) market is expected to reach USD 1.2 billion …
Epidemic keratoconjunctivitis (EKC) is a highly contagious ocular infection caused primarily by adenoviruses, presenting with severe conjunctival inflammation, corneal involvement, pain, and vision disturbances. Outbreaks are common in healthcare settings, schools, and workplaces, leading to significant public health and economic burdens.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71737
With no approved antiviral therapy currently available, management relies on supportive care, hygiene measures, and off-label treatments such as povidone-iodine or…
Community-Acquired Bacterial Pneumonia (CABP) Market is expected to reach USD 14 …
Community-acquired bacterial pneumonia (CABP) is a serious lung infection contracted outside hospital or healthcare settings, most commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and other bacterial pathogens. It remains a leading cause of morbidity, mortality, and healthcare costs worldwide, particularly among children, elderly populations, and immunocompromised patients.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71735
The CABP market is driven by rising incidence, antimicrobial resistance (AMR), approvals of…
Athlete's Foot (Tinea Pedis) Market is expected to reach USD 5.9 billion by 2034
Athlete's foot, or tinea pedis, is a highly common contagious fungal infection of the feet caused mainly by Trichophyton species. Symptoms include itching, redness, scaling, fissures, and discomfort, often spreading to toenails and hands if untreated. It is typically transmitted in warm, moist environments such as locker rooms, gyms, and swimming pools, and is more prevalent among athletes, diabetics, and immunocompromised individuals.
Download Full PDF Sample Copy of Market Report @…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
